Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2024-05-16 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-05-16 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2024, reporting the submission of matters to a vote of security holders at the 2024 Annual Meeting of Stockholders. It details the voting results on director elections, ratification of the independent auditor, advisory approval of executive compensation, and approval of amendments to an equity incentive plan. The content focuses exclusively on the official results of shareholder votes at the annual meeting. There is no financial data or detailed report content, only voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is sufficient and the content is substantive for this category, not merely an announcement of a report publication or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2024-05-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 8, 2024. It announces the issuance of a press release regarding the company's financial results for the first quarter ended March 31, 2024, and mentions a conference call scheduled to discuss these results. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 3855 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) and not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings announcing events or press releases.
2024-05-08 English
FORM DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, specifically a Definitive Additional Materials filing related to a proxy statement. It includes a letter from the CEO to stockholders discussing company accomplishments, outlook, governance changes, and equity incentive plan amendments. The presence of proxy statement language, references to board refreshment, governance best practices, and equity plan amendments clearly indicate this is related to executive compensation and governance matters typically disclosed in proxy filings. The form DEFA14A is a known SEC form used for proxy solicitation materials, often including remuneration information. Therefore, the document fits the Remuneration Information category (DEF 14A). The document length and content confirm it is not a brief announcement or a simple report publication notice but a substantive filing. Confidence is high due to explicit form type and content.
2024-04-29 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares by selling stockholders following a merger. It includes detailed information about the offering, risk factors, use of proceeds, selling stockholders, and plan of distribution. The document is not an earnings release, annual report, or management discussion but a registration prospectus for a share offering. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through a share resale offering. The document length is substantial and contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2024-04-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.